Prosecution Insights
Last updated: October 02, 2026
Application No. 17/277,829

STEROL ANALOGS AND USES THEREOF

Non-Final OA §OTHER§Other
Filed
Mar 19, 2021
Priority
Sep 19, 2018 — provisional 62/733,540 +3 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
ModernaTX Inc.
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
842 granted / 1137 resolved
+14.1% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
63 currently pending
Career history
1184
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.3%
-23.7% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
49.6%
+9.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1137 resolved cases

Office Action

§OTHER §Other
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/1/2026 has been entered. Status of Claims Claims 1,189,203 and 266-272 are pending in the instant application. Claim 203 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1,189, and 266-272 is contained herein. The examiner has expanded the search to cover the species of formula Ia. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 10/2/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 4/1/2026. Status of Rejections 35 USC § 102(a)(2) The 102(a)(2) rejection of claims 1,189, and 266-272 is still maintained with respect to US Patent Application 2022/0296517. Applicant’s arguments, see Remarks, filed 4/1/2026, with respect to the Final Office Action mailed 10/2/2025, have been fully considered but are not found persuasive. To reiterate the rejection of record; US 2022/0296517 teach the following compounds at page 179 (example 19) and at page 186 (example 184): PNG media_image1.png 176 552 media_image1.png Greyscale PNG media_image2.png 160 576 media_image2.png Greyscale wherein the compounds falls within the scope of Formula Ia, wherein X = O, R1b = H or triisopropylsilyl, R3 = methyl, L1a-1c = alkyl or alkylsulfonyl, n14 = 0, and Y3 =-Nmethyl or S. Thus the claims are anticipated. Applicants argues that the document does not serve as prior art based on the earliest priority date of August 7, 2019, while the instant claims receive the benefit of USSN 62/798,752 which has a filing date of January 30, 2019. The examiner respectfully disagrees. Applicants are reminded that the examiner stated of record that this application is a 371 of PCT/US19/51959 and claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent App No. 62/733,540, filed 9/19/2018 and 62/798,752 filed 1/30/2019. Benefit for the provisional applications are not accorded since subject matter disclosed within the instant application is not supported (e.g. formula I and full scope of embodiments recited therein, e.g. R1b, etc.). The claims in a U.S. application are entitled to the benefit of a foreign priority date or the filing date of a provisional application if the corresponding foreign application or provisional application supports the claims in the manner required by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph. In re Ziegler, 992 F.2d 1197, 1200, 26 USPQ2d 1600, 1603 (Fed. Cir. 1993); Kawaiv.Metlesics, 480 F.2d 880, 178 USPQ 158 (CCPA 1973); In re Gosteli, 872 F.2d 1008, 10 USPQ2d 1614 (Fed. Cir. 1989). In the instant case despite being limited to the formula Ia; USSN 62/798,752 does not support the claimed subject matter with respect to variable L1b being selected from the cis alkene shown below: PNG media_image3.png 52 406 media_image3.png Greyscale . Thus, the document may still serve as prior art and the rejection is maintained. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Mar 19, 2021
Application Filed
Mar 20, 2025
Non-Final Rejection mailed — §OTHER, §Other
Aug 20, 2025
Response Filed
Oct 02, 2025
Final Rejection mailed — §OTHER, §Other
Apr 01, 2026
Request for Continued Examination
Apr 03, 2026
Response after Non-Final Action
May 14, 2026
Non-Final Rejection mailed — §OTHER, §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747223
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
3y 3m to grant Granted Sep 29, 2026
Patent 12741943
Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use
4y 0m to grant Granted Sep 22, 2026
Patent 12741959
Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
2y 6m to grant Granted Sep 22, 2026
Patent 12733635
PLATELET STORAGE METHODS AND COMPOSITIONS
4y 2m to grant Granted Sep 15, 2026
Patent 12735403
SALT OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, SOLID FORM OF THE SALT, PREPARATION METHOD FOR SAME, AND USES THEREOF
3y 6m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.8%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1137 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month